Jefferies Downgrades PTC Therapeutics (PTCT) to 'Hold' with Price Target Adjustment | PTCT Stock News

NodeGuardian · 2026-04-12T10:20:24+00:00

Jefferies downgraded PTC Therapeutics to 'Hold,' cutting its price target from $91 to $76, a 16.48% decrease. Despite this, analysts project a potential 31.12% upside, though another estimate indicates a 45.73% downside.

NodeGuardian

2026-04-12 10:20:24

Abstract generation in progress

Jefferies has downgraded PTC Therapeutics (PTCT) from a ‘Buy’ to a ‘Hold’ rating, lowering its price target from $91.00 to $76.00. This adjustment reflects a 16.48% decrease and follows a series of recent analyst actions with varying ratings and price targets. Despite the downgrade, the average one-year price target from 15 analysts is $86.07, suggesting a potential upside of 31.12% from the current price, though GuruFocus’ GF Value estimates a 45.73% downside.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.